Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a 12% revenue growth and improved net loss, indicating positive financial performance. However, the lack of strategic updates and guidance, combined with forward-looking risks, tempers enthusiasm. Improved gross margins are a positive sign, but the slight increase in operating expenses and reduced cash reserves are potential concerns. The absence of Q&A insights and strategic initiatives further supports a neutral outlook.
Key Financial Performance
Revenue Xeris Biopharma reported a revenue of $34.5 million for Q1 2026, representing a 12% increase year-over-year. The growth was attributed to strong sales of their lead product and expanded market penetration.
Net Loss The company reported a net loss of $8.2 million for Q1 2026, which is an improvement compared to the $10.5 million net loss in Q1 2025. The reduction in net loss was due to improved operational efficiencies and cost management.
Gross Margin Gross margin improved to 68% in Q1 2026 from 65% in Q1 2025, driven by better product mix and manufacturing efficiencies.
Operating Expenses Operating expenses were $22.3 million in Q1 2026, a slight increase from $21.8 million in Q1 2025. The increase was primarily due to higher R&D investments.
Cash and Cash Equivalents The company ended Q1 2026 with $45 million in cash and cash equivalents, compared to $50 million at the end of Q1 2025. The decrease was attributed to ongoing investments in product development and commercialization efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations. This includes risks outlined in SEC filings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alexandra von
Bank Jefferies
Biopharma Holdings
Brandon Folkes
CEO Director
Chief Financial
Co LLC
Communications CEO
Conference Instructions
Director Pieper
Division Alexandra
Division Brandon
Division EDT
Division Georgia
Division Jason
Dorr Oppenheimer
EDT Xeris
Folkes HC
Georgia Bank
HC Wainwright
Inc Senior
Instructions opening
Jason Dorr
Jefferies LLC
LLC Research
Officer Chase
Riesemann Piper
Wainwright Co
Xeris Biopharma
remark statement
today date
von Riesemann
XERS Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a 12% revenue growth and improved net loss, indicating positive financial performance. However, the lack of strategic updates and guidance, combined with forward-looking risks, tempers enthusiasm. Improved gross margins are a positive sign, but the slight increase in operating expenses and reduced cash reserves are potential concerns. The absence of Q&A insights and strategic initiatives further supports a neutral outlook.
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call shows strong financial performance with a 15% revenue increase and a shift from net loss to net income. Improved gross margins and cash flow further support a positive outlook. Despite risks in forward-looking statements, the raised revenue guidance and strategic investments indicate confidence in future growth. These factors suggest a positive stock price movement in the short term.
Zurich Insurance Group AG (ZUR:CA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call presents a positive outlook with raised revenue guidance, strong product performance, improved gross margin, and positive adjusted EBITDA. The Q&A section reinforces this sentiment with positive rate developments and growth strategies. Despite some management vagueness, the overall tone is optimistic, indicating potential stock price appreciation.
XERS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
